MedTrace Logo

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

NCT03436693 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2026-01-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Canagliflozin

Canagliflozin 100mg orally once daily

DRUG

Placebo

Placebo orally once daily

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2021-01-21
Completion
2021-01-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03436693 on ClinicalTrials.gov